Try our Advanced Search for more refined results
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Barnow & Associates
- Baron & Budd
- Barton & Burrows
- Beasley Allen
- Berkowitz Oliver
- Berman Tabacco
- Blood Hurst
- Boies Schiller
- Bradford & Wilson
- Burns Charest
- Bush Seyferth
- Butler Prather
- Carella Byrne
- Clark Hill
- DiCello Levitt
- Dollar Burns
- Foley & Lardner
- Foulston Siefkin
- Fredrikson & Byron
- Freshfields
- Gibbons PC
- Gibbs Law Group
- Gibson Dunn
- GM Law PC
- Goldman Scarlato
- Goodwin Procter
- Groom Law Group
- Gustafson Gluek
- Hagens Berman
- Hinkle Law Firm
- Hogan Lovells
- Holland & Knight
- Horn Aylward
- Joseph Saveri Law Firm
- Kaufman & Canoles
- Keller Rohrback
- King & Spalding
- Kramer Levin
- Lanier Law Firm
- Latham & Watkins
- Lathrop GPM
- Law Offices of Ursula Taylor
- Levi & Korsinsky
- Lightfoot Franklin
- Lockridge Grindal
- Lowey Dannenberg
- Marion's Inn
- Matthew G. Miller PC
- Mayer Brown
- McCune Wright
- Mehri & Skalet
- Pallas Partners
- Parker Waichman
- Perkins Coie
- Pritzker Levine
- Reed Smith
- Robbins Geller
- Robbins Russell
- Robins Kaplan
- Saiber LLC
- Scott&Scott
- Sharp Law LLP
- Shook Hardy
- Sidley Austin
- Siegfried & Jensen
- Spencer Fane
- Spragens Law
- Squitieri & Fearon
- Steven Williams Law
- Strategic Health Law
- Wagstaff & Cartmell
- Weil Gotshal
- White & Case
- Williams & Connolly
- Willkie Farr
- Wilson Sonsini
- Yarmuth LLP
Companies
- Aetna Inc.
- Amerigroup Corp.
- Centene Corp.
- Change Healthcare Inc.
- Coventry Health Care Inc.
- CVS Health Corp.
- Express Scripts Holding Co.
- Humana Inc.
- King Pharmaceuticals Inc.
- MedImpact Healthcare Systems Inc.
- Meridian Medical Technologies Inc.
- Optum Inc.
- OptumRx Inc.
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- The Segal Co. Inc.
- UnitedHealth Group Inc.
- Viatris Inc.
Sectors & Industries:
-
July 01, 2019
Sanofi Casting Blame For Failed EpiPen Rival, Mylan Says
Mylan urged a Kansas federal judge Friday to nix Sanofi's antitrust allegations in a broader multidistrict litigation, arguing that its EpiPen competed with Sanofi's epinephrine auto-injector fair and square, only for the latter's product to fail and Sanofi to foist the blame on Mylan.
-
January 24, 2019
Sanofi Suit Against Mylan To Stay In EpiPen MDL, For Now
Sanofi's allegations that Mylan illegally protected its EpiPen monopoly will remain tied into consumers' related multidistrict litigation in Kansas, a federal judge ruled Wednesday, as he found splitting the similar antitrust cases doesn't make sense now, but noted Sanofi's remand chances will look better closer to trial.
-
December 18, 2018
EpiPen MDL Gets Special Master To Deal With Disputed Docs
A Kansas federal court has appointed a special master to settle a discovery dispute between Mylan and Sanofi in multidistrict litigation over EpiPen price hikes after the companies failed to sort out their disagreements over more than 2,000 documents on Sanofi's privilege log.
-
December 14, 2018
EpiPen MDL Attys Scolded For 'Mindless Bickering'
A Kansas federal judge on Friday dressed down attorneys in multidistrict litigation over EpiPen price hikes for engaging in "mindless bickering" during a high-stakes deposition of Mylan NV's chief executive officer.
-
December 14, 2018
Sanofi Fires Back Against Mylan In Its Bid To Exit EpiPen MDL
Sanofi-Aventis US LLC told a Kansas federal court Friday that Mylan Inc. missed the mark when pointing to overlaps between Sanofi's case accusing the EpiPen maker of employing anti-competitive tactics and suits from consumers over prices of the drug, arguing there's enough difference to warrant transferring its case out of multidistrict litigation.
-
December 03, 2018
EpiPen Maker Slams Sanofi's Bid To Exit Antitrust MDL
Sanofi should not yet be allowed to leave multidistrict litigation to pursue claims elsewhere that EpiPen maker Mylan used anti-competitive practices to hurt sales of Sanofi's competing emergency allergy treatment, Mylan told a Kansas federal court Friday.
-
November 01, 2018
Sanofi Wants Claims Against Mylan Out Of EpiPen MDL
Sanofi-Aventis US LLC urged a Kansas federal court on Thursday to recommend its suit accusing EpiPen maker Mylan Inc. of using anti-competitive practices to hurt sales of its competing emergency allergy treatment be transferred out of multidistrict litigation over the drug.
-
October 02, 2018
Consumers Seek Sanctions For Mylan In EpiPen Pricing Suit
A potential class of consumers has asked a Kansas federal judge to sanction Mylan NV for allegedly interfering with discovery and withholding documents and emails that consumers are seeking in an antitrust suit alleging the pharmaceutical company drove up the price of emergency allergy treatment EpiPen.
-
September 25, 2018
Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield
A long-standing U.S. Supreme Court doctrine shielding companies that petition the U.S. Food and Drug Administration from antitrust liability is proving increasingly unhelpful to brand-name drugmakers accused of delaying generic-drug rivals by bombarding the FDA with cockamamie scientific arguments.
-
September 06, 2018
Mylan Decries 'Hopeless Fishing Expedition' In EpiPen MDL
Mylan NV assailed an effort to access more of its CEO’s emails in multidistrict litigation over price hikes for emergency allergy treatment EpiPen, calling the bid a “hopeless fishing expedition” motivated by failures to uncover evidence of C-suite misconduct.